Epigenetic mechanisms, which include DNA methylation, histone modification, and
microRNA (miRNA), can produce heritable phenotypic changes without a change in DNA …

For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

Protein lysine methylation is a crucial post-translational modification that regulates the
functions of both histone and non-histone proteins. Deregulation of the enzymes or 'writers' …

Standard induction chemotherapy, consisting of an anthracycline and cytarabine, has been
the first-line therapy for many years to treat acute myeloid leukemia (AML). Although this …

Haematopoiesis is governed by haematopoietic stem cells (HSCs) that produce all lineages
of blood and immune cells. The maintenance of blood homeostasis requires a dynamic …

Cancer was thought to be caused solely by genetic mutations in oncogenes and tumor
suppressor genes. In the last 35 years, however, epigenetic changes have been …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …

Hematopoiesis is the process by which both fetal and adult organisms derive the full
repertoire of blood cells from a single multipotent progenitor cell type, the hematopoietic …

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy.
Current intensified therapeutic protocols coincide with severe side effects, and no salvage …

Acute myeloid leukemia (AML) is a polyclonal and heterogeneous hematological
malignancy. Relapse and refractory after induction chemotherapy are still challenges for …